Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Ambrx Biopharma Inc ADR
(NY:
AMAM
)
10.13
UNCHANGED
Last Price
Updated: 7:00 PM EDT, Mar 16, 2023
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about Ambrx Biopharma Inc ADR
< Previous
1
2
Next >
Ambrx Biopharma Inc. to Release Full Year 2021 Financial Results on Tuesday, April 26, 2022
April 21, 2022
From
Ambrx, Inc.
Via
Business Wire
Ambrx Biopharma Inc. Announces Submission of IND Application for ARX305 with the U.S. FDA
February 15, 2022
From
Ambrx, Inc.
Via
Business Wire
Ambrx Biopharma Inc. Appoints Paul Maier to Board of Directors and as Chair of the Audit Committee
February 07, 2022
From
Ambrx, Inc.
Via
Business Wire
Ambrx Biopharma Inc. Presents Positive Data from Ongoing ACE-Breast-01 Phase 1 Clinical Study of ARX788 at San Antonio Breast Cancer Symposium
December 09, 2021
From
Ambrx Biopharma Inc.
Via
Business Wire
Ambrx Biopharma Inc. Announces Acceptance of Two Poster Presentations at the 2021 San Antonio Breast Cancer Symposium
November 19, 2021
From
Ambrx, Inc.
Via
Business Wire
Ambrx Biopharma Inc. Announces First Patient Dosed in its Global Phase 2 ACE-Breast-03 Clinical Study of ARX788 for the Treatment of HER2-Positive Metastatic Breast Cancer
November 04, 2021
From
Ambrx, Inc.
Via
Business Wire
Ambrx Biopharma Inc. to Present at the 30th Annual Virtual Credit Suisse Healthcare Conference
November 01, 2021
From
Ambrx, Inc.
Via
Business Wire
Ambrx Biopharma Inc. Reports 1H 2021 Financial Results and Provides Corporate Update
October 28, 2021
From
Ambrx, Inc.
Via
Business Wire
Ambrx Announces Positive Data on ARX788 for the Treatment of HER2+ Gastric Cancer Presented at CSCO
October 04, 2021
From
Ambrx, Inc.
Via
Business Wire
Ambrx to Participate in Panel Discussion at the H.C. Wainwright 23rd Annual Global Investment Conference
September 09, 2021
From
Ambrx, Inc.
Via
Business Wire
Ambrx Announces First Patient Dosed in a Phase 1 Trial for ARX517, an ADC in Development to Treat PSMA Expressing Tumors
August 03, 2021
From
Ambrx
Via
Business Wire
Ambrx Appoints Sonja Nelson as Chief Financial Officer
June 30, 2021
From
Ambrx
Via
Business Wire
Ambrx Announces Pricing of Initial Public Offering
June 17, 2021
From
Ambrx
Via
Business Wire
< Previous
1
2
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.